Company Overview
Vision and Mission
Leadership Team
Board of Directors
ESG
The United Nations Global Compact
Contact Us
Pipeline and Major Products
Discovery
Manufacturing
Partners
Press Releases
Media Coverage
Awards
Presentations and Webcasts
Announcements and Circulars
Financial Reports and Listing Documents
Analyst Coverage
Corporate Governance
Events Calendar
IR Contact and Email Alert
Job Opportunities
Everest Medicines and Providence Therapeutics Jointly Announce Vaccine Development Strategy to Address Omicron (B.1.1.529) SARS-CoV-2 Variant
Everest Medicines Announces Inclusion in the MSCI Global Small Cap Indexes - MSCI China Index
Everest Medicines and Gilead Sciences Jointly Announce Phase 2b Study of Sacituzumab Govitecan Conducted in China of Patients with Metastatic Triple-Negative Breast Cancer Meets Primary Overall Response Rate Endpoint
Everest Medicines Announces Up to HK$100 million Additional Share Repurchase Program
Everest Medicines Announces Share Repurchase Transaction Details
Everest Medicines Initiates Submission of New Drug Application in Hong Kong for XeravaTM for the Treatment of Complicated Intra-abdominal Infections
Everest Medicines Announces Approval of Investigational New Drug Application by China NMPA for SPR206
AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies
Everest Medicines, Sinovent and SinoMab Announce Licensing Agreement for Global Development, Manufacturing and Commercialization of Novel BTK Inhibitor in Renal Diseases
Everest Medicines Enters into Comprehensive Agreements with Providence Therapeutics to Advance mRNA Vaccines and Therapies, including COVID-19 Vaccines, in Asia Emerging Markets
Everest Medicines Announces Half-Year 2021 Interim Results
Everest Medicines Announces Up to HK$100 million Share Repurchase Program
Everest Medicines Announces First Person Dosed in Global Phase 3 Registration Trial of Sacituzumab Govitecan-Hziy in China for Metastatic Urothelial Cancer
Everest Medicines to Announce Half-Year 2021 Interim Results
Everest Medicines Announces Approval of Clinical Trial Application by China NMPA for Phase 3 Trial of XeravaTM for Community-Acquired Bacterial Pneumonia
Everest Medicines Receives Pediatric and Rare Severe Disease Priority Review Designation from Taiwan FDA for Sacituzumab Govitecan-Hziy in Metastatic Triple-Negative Breast Cancer
Everest Medicines Announces Strategic Collaboration with MediTrust Health Co., Ltd to Develop Novel Payment Solutions for Patients in China
Everest Medicines Announces Strategic Collaboration with Medbanks Health Technology to Develop Innovative Healthcare Service Solutions for Patients in China
Everest Medicines Announces Strategic Commercial Partnership with Global Technology Company, Tencent
Everest Medicines Announces that Spero Therapeutics Entered into Licensing Agreement with Pfizer Inc. for SPR206 in ex-U.S. and ex-Asia Territories